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Abstract: The phosphorylation of Amyloid Precursor Protein (APP) at Thr668 plays a key 
role in APP metabolism that is highly relevant to AD. The c-Jun-N-terminal kinase (JNK), 
glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (Cdk5) can all be 
responsible for this phosphorylation. These kinases are activated by excitotoxic stimuli 
fundamental hallmarks of AD. The exposure of cortical neurons to a high dose of NMDA 
(100 μM) for 30’-45’ led to an increase of P-APP Thr668. During NMDA stimulation APP 
hyperphosphorylation has to be assigned to GSK-3β activity, since addition of L803-mts, a 
substrate competitive inhibitor of GSK-3β reduced APP phosphorylation induced by 
NMDA. On the contrary, inhibition of JNK and Cdk5 with D-JNKI1 and Roscovitine 
respectively did not prevent NMDA-induced P-APP increase. These data show a tight 
connection, in excitotoxic conditions, between APP metabolism and the GSK-3β signaling 
pathway. 
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1. Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly. One of the 
pathological hallmarks of AD is the abnormal accumulation of amyloid-β (Aβ) produced by 
proteolytic cleavage of the Amyloid Precursor Protein (APP). APP processing is influenced by post-
translational modifications, N- and O-glycosylations, and phosphorylations that can induce a 
preferential cleavage of APP in the amyloidogenic pathway eventually leading to Aβ production [1,2]. 
In particular the hyperphosphorylation of APP at Threonine 668 (Thr668) in the cytoplasmic domain 
plays a pivotal role in APP processing and is highly relevant to AD [3].  
The candidate kinases, responsible for Thr668 phosphorylation, are three: Cyclin-dependent kinase 5 
(Cdk5), glycogen synthase kinase-3β (GSK-3β) and c-jun-N-terminal kinase (JNK) [4-7], but the 
conditions and the precise role of these kinases in APP metabolism have still to be elucidated [8]. 
These three kinases are also associated with neurotoxicity [9,10] and are implicated in Alzheimer’s 
disease [5,6,11,12]. 
Amongst them, JNK is a key pathway in excitotoxicity [13–15], Aβ toxicity [16] and AD pathology 
[3] and modulates APP phosphorylation in differentiated neurons [7,17]. Cdk5 is another kinase with 
an important role in excitotoxicity [18] as well as AD pathogenesis [19]. Cdk5 and its activator p25 
accumulate in neurons during oxidative stress and treatment with Aβ [9,10,20], while altered 
Cdk5/p25 levels have been reported in AD brains [21].  
Finally, GSK-3β is of particular relevance to neurological disorders since it phosphorylates APP at 
Thr668, as well as Tau and Presenilin1 [22–24], inducing amyloid plaques and neurofibrillary tangles 
formation [25]. An abnormal increase of GSK-3β activity is associated with AD pathogenesis [26] and 
inhibition of GSK-3β hyperactivation induced by exposure of neurons to Aβ peptide, prevents 
neurodegeneration [27]. Moreover GSK-3β inhibition reduces neuronal death in models of oxygen-
glucose deprivation as well as glutamate excitotoxicity in vitro [28]. 
Because glutamate plays a key role in AD pathology and NMDA stimulation for prolonged periods 
leads to increased production and secretion of Aβ fragments in primary neuronal cultures [29] we 
investigated APP phosphorylation at Thr668 in cortical neurons stimulated with a high dose of NMDA 
(100 μM). This dose of NMDA correlated with an increase in APP phosphorylation and 
amyloidogenic processing (β-APPs) and led to activation of all three kinases without causing neuronal 
death in this short temporal window.  
2. Results and Discussion 
2.1. NMDA treatment of cortical neurons 
Cortical neurons were exposed to N-methyl-D-aspartate (NMDA) 100 μM for 30’-45’. As reported 
previously by Borsello et al., this dose of NMDA induces 90% neuronal death after 24 h [15]. Instead, 
in the temporal window used in our experiments, NMDA administration did not induce neuronal death 
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as demonstrated by LDH analysis and Hoechst staining (Figure 1, a-b). Following 30’-45’ NMDA 
stimulation, some neurons presented a swelling appearance with enlarged nuclei, a hallmark of 
neuronal death (Figure 1b, B-C arrows).  
Figure 1. Neuronal death is not induced after 30’-45’ NMDA application. (a) Neurons 
were exposed to NMDA (30’-45’-1 h) and neuronal viability was assessed by LDH assay. 
NMDA-1h significantly increased neuronal death. Quantification is from five independent 
experiments (±S.E.M.), (* p < 0.05). (b) Hoechst staining of neurons exposed to NMDA. 
At 30’-45’, NMDA induces some neuronal swelling (arrows fig. B-C, magnification 20 × 
and higher magnification (40 ×) in the box B). After 1 h some neurons undergo nuclear 
fragmentation (arrows fig. D) while we can also note the presence of the first “ghost” 
neuron (arrowheads fig. D; higher magnification (40 ×) in the box).  
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The first clear signs of neuronal death became apparent after 1 h of NMDA stimulation, with (a) a 
significant increase in LDH release in comparison to control and NMDA treated cultures for 30’-45’ 
(b) nuclear fragmentation (Figure 1b, D arrows) and (c) the presence of “ghosts” neurons (denucleated 
neurons with an unstained shadowy center where the nucleus used to be) (Figure 1b, D arrowheads) 
further underlying that at this point NMDA becomes toxic.  
2.2. NMDA for 30’-45’ induces APP hyperphosphorylation at Thr668 
Application of 100 μM NMDA in cortical neurons induced hyperphosphorylation of APP at Thr668. 
P-APP was normalized against the total APP using the 22C11 antibody that recognizes the APP full 
length (Figure 2, a). Quantification of western blots revealed that, compared to control conditions, 
NMDA application increased APP phosphorylation at Thr668. In particular, at 30’ the P-APP/APP ratio 
reached 1.7 fold increase (p = 0.02) and at 45’ rose further (2.1-fold increase, p = 0.003) (Figure 2b). 
Total APP protein levels were not affected by NMDA treatment (Figure 2, d). The ratio APP/tubulin 
did not change, while the ratio P-APP/tubulin increased confirming the augmentation of P-APP 
(Figure 2, c). Notably, NMDA resulted in an increase of the secreted APPs fragments in the 
corresponding neuronal media (Figure 2, e). More specifically, by 45’ we observed a 1.7-fold increase 
(p = 0.003), (Figure 2, f). 
Moreover NMDA treatment induced a significant increase in the amyloidogenic processing of APP 
as demonstrated by the increase of βAPPs/APP ratio after 45’ (p = 0.02) and reduction of αAPPs/APP 
ratio at 30’-45’ (p = 0.037 and p = 0.039) (see Figure 3, a-b-c). These results suggest that NMDA 
stimulation, not only induces an increase in APP phosphorylation, but promotes the amyloidogenic 
processing by increasing βAPPs in the media. 
2.3. NMDA stimulation induces JNK, Cdk5 and GSK-3β 
Because JNK, Cdk5 and GSK-3β kinases can all contribute to APP phosphorylation at Thr668 we 
studied their activation following NMDA stimulation.  
(1) JNK. In agreement with our previous reports [14,15], we could show that NMDA induces JNK 
activation both at 30’ and 45’ (1.3- and 1.75-fold, p = 0.03) as shown by quantification of the P-
JNK/JNK ratio (Figure 4, a-b).  
(2) Cdk5. The effect of NMDA on Cdk5 activity was examined with Cdk5 immunoprecipitation 
kinase assays using histone H1 as protein kinase substrate. NMDA application for 45’ induced a 
significant increase (1.8-fold, p = 0.05) in Cdk5 activity (Figure 4, c-d).  
(3) GSK-3β. Concomitantly, NMDA application led to a powerful activation of GSK-3β (here 
expressed as a decrease of the inhibitory phosphorylation in Ser-9). GSK-3β  phosphorylation 
decreased to 0.5 (p = 0.002) by 30’, to reach a 0.7 value (p = 0.0002) by 45’ (Figure 4, e-f).  
These results demonstrate that NMDA treatment leads to the activation of all three kinases, 
indicating the involvement of complex signaling mechanisms. 
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Figure 2. NMDA application induces APP hyperphosphorylation. (a) Neurons were 
exposed to NMDA (30’-45’), cell lysates were immunoblotted for P-APP and total-APP. 
Loading control: Tubulin. (b) Quantification showed that NMDA increased P-APP level 
(P-APP/APP ratio), at 30’ (70%) and 45’ (110%). (c) NMDA increased P-APP/Tub ratio 
after 45’ (60%). (d) NMDA did not affect the total-APP protein level (APP/Tub). (e) 
Proteins from culture media were blotted for total-APP secreted (APPs). Loading control: 
Total medium proteins identified with Coomassie Blue. (f) NMDA-45’ treatment increased 
APPs level (70%). Quantifications are from six independent experiments (±S.E.M.), * p < 
0.05, ** p < 0.01. 
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Figure 3. Inhibition of GSK-3β and APP amyloidogenic processing. (a) NMDA induces 
an increase in the APP amyloidogenic processing as shown by the increase of βAPPs and 
the decrease of αAPPs fragments. (b) Quantification showed a significant increase of 
βAPPs/APP ratio during NMDA-45’ treatment (p = 0.02) in comparison to untreated 
controls. L803-mts/NMDA-45’ treatment reduced βAPPs levels, this reduction is not 
significant compared to NMDA-45’ treatment. (c) NMDA reduced the αAPPs/APP ratio at 
30’-45’ (p = 0.037, p = 0.039) compared to untreated controls. Instead, L803-mts induced 
an increase of the αAPPs/APP ratio, although it was not able to restore control levels. 
Loading control: Tubulin. Quantifications are from three independent experiments 
(±S.E.M.), * p < 0.05. 
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Figure 4. JNK, Cdk5 and GSK-3β are activated following NMDA application. (a) NMDA 
increased JNK activity as revealed by the increment of P-JNK. (b) Quantification showed a 
30% and 75% increase in JNK activity at 30’-45'. (c) Cdk5 activity assay showed an 
increase in enzyme activity after NMDA-45’. (d) Quantification confirmed an 80% 
induction of Cdk5 activity after NMDA-45’. (e) Neurons were exposed to NMDA and 
blotted for P-GSK-3β and total GSK-3β. (f) NMDA induced an increase of GSK-3β 
activity at 30’ (50%) and 45’ (70%). Loading control: Tubulin. Quantifications are from 
six independent experiments (±S.E.M.), * p < 0.05, ** p < 0.01. 
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2.4. Neither JNK nor Cdk5 are responsible for NMDA induced APP hyperphosphorylation  
As previously shown, in control conditions, D-JNKI1 treatment for 24h prevented APP 
phosphorylation on Thr668 in cortical neurons [17]. To investigate the role of JNK in APP 
phosphorylation following NMDA application we used the same D-JNKI1 inhibitor. Neurons were 
pre-treated with D-JNKI1 (4 μM) 30’ before NMDA stimulation and the P-APP/APP ratio was 
compared to untreated neurons (Figure 5, a). D-JNKI1 did not prevent NMDA-induced APP 
phosphorylation as shown by quantification of Western blots (Figure 5, b). On the contrary, D-
JNKI1/NMDA co-treatment induced an increase of P-APP compared to NMDA alone. Application of 
D-JNKI alone or with NMDA did not lead to neuronal death (see Figure 6). 
We can conclude that NMDA-induced hyperphosphorylation of APP is not mediated by JNK.  
We then investigated the role of Cdk5 in our model. To prevent Cdk5 action we used the ATP 
competitive inhibitor Roscovitine, a well-characterized inhibitor of cdc-2 like kinases and the most 
common inhibitor to block Cdk5 activity [30].  
Figure 5. JNK and Cdk5 inhibition do not reverse NMDA induced APP 
hyperphosphorylation. (a) Neurons were pre-treated with D-JNKI1 and then exposed to 
NMDA (30’-45’). (b) Western blot analysis and quantification showed that co-treatment with 
D-JNKI1/NMDA did not reduce P-APP increment induced by NMDA alone. On the contrary, 
D-JNKI1 pre-treatment increased P-APP/APP level. (NM = NMDA, DJ = D-JNKI1) (c) 
Neurons were pre-treated with Roscovitine and then exposed to NMDA. (d) Roscovitine did 
not reduce P-APP following NMDA application. Roscovitine/NMDA co-treatment further 
increased P-APP/APP levels compared to controls. (Ros = Roscovitine) Loading control: 
Tubulin. Quantifications are from six independent experiments (±S.E.M.), * p < 0.05,  
** p < 0.01. 
.  
 
Pharmaceuticals 2010, 3                
 
 
50
Figure 6. Neurons were exposed to NMDA (30’-45’-1 h) and neuronal viability was 
assessed by LDH assay. Application of D-JNKI alone or in combination with NMDA  
(30’-45’) did not affect neuronal survival. NMDA for 1 h significantly increased neuronal 
death while treatment with D-JNKI protected neurons. Quantification is from five 
independent experiments (±SEM), (∗ p < 0.05). 
 
 
Neurons were pre-treated with Roscovitine (10 μM) for 30’ before NMDA administration and the 
P-APP/APP ratio was compared to untreated neurons. Roscovitine effectively blocked NMDA induced 
activation of Cdk5 but did not reduce APP phosphorylation levels. Quantification of P-APP/APP ratio 
confirmed that there was no significant reduction in the Roscovitine/NMDA samples compared to 
NMDA alone (Figure 5, c-d).  
Thus Cdk5 does not play a pivotal role in NMDA mediated hyperphosphorylation of APP.  
2.5. GSK-3β regulates NMDA induced APP hyperphosphorylation  
To examine if GSK-3β plays a role in NMDA induced hyperphosphorylation we used L803-mts, a 
small cell permeable peptide, which competes for the substrate binding site of GSK-3β [31]. 
Application of L803-mts (10 μM) 30’ before NMDA stimulation led to a reduction of APP 
phosphorylation during NMDA stimulation at 45’ compared to NMDA alone (p = 0.0006). Notably at 
45’, P-APP levels in L803-mts/NMDA treated neurons were comparable to those of non-treated 
control neurons (Figure 7, a-b) underlying the fundamental role of GSK-3β in this process. We 
conclude that GSK-3β is the kinase responsible for NMDA mediated hyperphosphorylation of APP. 
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Figure 7. L803-mts action on APP phosphorylation. (a) Neurons were pre-treated with L803-
mts and then exposed to NMDA (30’-45’). Western blot analysis shows that L803-
mts/NMDA co-treatment inverts the increase of P-APP/APP ratio following NMDA 
administration. (b) Quantification revealed a significant reduction (65%) of P-APP in L803-
mts/NMDA-45’ neurons compared to NMDA-45’(#=p < 0.05). Loading control: Tubulin. 
Quantifications are from six independent experiments (±S.E.M.), * p < 0.05, ** p < 0.01.  
 
 
2.6. GSK-3β regulates APP amyloidogenic processing induced by NMDA stimulation 
To detect the effect of L803-mts during NMDA treatment on APP amyloidogenic processing we 
analysed the level of βAPPs (amyloidogenic pathway) and αAPPs fragments (non-amyloidogenic 
pathway) (Figure 3, a). As described above, NMDA treatment induced a significant increase of βAPPs 
and a decrease of αAPPs fragments. Following treatment of NMDA stimulated neurons with L803-
mts, the βAPPs/APP ratio returned to almost control levels (Figure 3, b), while the αAPPs/APP ratio 
showed a clear tendency to increase (Figure 3, c).  
These results indicate that L803-mts modulates the APP amyloidogenic processing induced by 
NMDA. 
2.7. Discussion 
Amyloid Precursor Protein metabolism has a fundamental role in AD pathogenesis. Very important 
in the processing of APP is the role of the phosphorylation at Thr668, in the C-terminal cytoplasmic 
domain of APP (AICD). Such phosphorylation facilitates β-secretase cleavage and can lead to an 
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increase in Aβ production [3]. It is thus important to elucidate the signaling pathways involved in this 
phosphorylation and how do they relate to different stressful stimuli. 
We investigated the impact of an excitotoxic stimulus such as NMDA on the phosphorylation of 
APP and on the activation of the three kinases that are involved in this phosphorylation, namely: JNK 
[6,17], Cdk5 [5,7] and GSK-3β [4].  
The neurotoxic effect of extracellular aggregates of Aβ peptide, derived from APP processing, is 
mediated by excitotoxic events such as dysregulation of Ca2+ homeostasis, oxidative stress and NMDA 
responses [32–35] and recent studies have demonstrated the close interaction between Aβ, Ca2+ 
homeostasis and oxidative stress through the NMDA receptors (NMDA-R) [36,37]. Concomitantly, 
the NMDA-R has important functions in synaptic transmission, synaptic plasticity and excitotoxicity 
[38] and deregulation of glutamatergic neurotransmission may contribute to the cognitive deficits 
present in AD. In fact, memantine, an NMDA receptor antagonist, is a drug used in the treatment of 
AD and can improve memory in AD patients [39,40].  
In order to investigate the direct effect of NMDA on APP, we stimulated 12 DIV fully 
differentiated cortical neurons with NMDA 100 μM for 30’-45’, a combination of concentration and 
duration that is not toxic for our neuronal in vitro model.  
Stimulation of cortical neuronal cultures with NMDA for 30’-45’ induces APP 
hyperphosphorylation at Thr668. Similar data were described by Hoey et al., [48]. Additionally, 
increment in P-APP correlated with an enhanced APP processing as shown by APPs release in 
neuronal media. Moreover in these conditions we observed an increase of βAPPs and a decrease of 
αAPPs fragments in neuronal lysates, confirming the important role of APP phosphorylation at Thr668 
for the APP amyloidogenic processing.  
At the same time, NMDA stimulation for 30’-45’ led to an increase in Cdk5 activity and, in 
agreement with others, induced an increase of GSK-3β [41] as well as JNK activation [14,15]. It is 
important to note that APP phosphorylation and activation of these kinases preceded neuronal 
degeneration, which only became evident after 1 h of NMDA application. 
In the second part of this study we investigated the role of Cdk5, GSK-3β and JNK in APP 
phosphorylation using specific kinase inhibitors. Although several studies have investigated the 
involvement of these kinases in APP phosphorylation their exact roles in models of excitotoxicity are 
still very unclear.  
We could show that inhibition of GSK-3β with a substrate competitive inhibitor (L803-mts) 
abolished NMDA induced APP phosphorylation after 45’ stimulation. Moreover we observed a 
positive effect of L803-mts on the APP amyloidogenic processing induced by NMDA treatment. In 
this short time window, the GSK-3β substrate competitive inhibitor led to a decrease of βAPPs 
production and an increase of αAPPs levels, even if it did not completely restore to control levels. This 
could be explained by the short-term treatment that is sufficient to significantly reduce P-APP levels 
but not all the APP processing.  
On the other hand, neither inhibition of Cdk5 by roscovitine, nor inhibition of JNK by D-JNKI 
reduced NMDA-induced APP hyperphosphorylation. Notably, inhibition of Cdk5 and/or JNK in 
NMDA stimulated neurons led to a further increase of APP hyperphosphorylation without affecting 
neuronal survival. Further studies are needed to elucidate the mechanisms behind such regulation. 
However we think that this data are not so surprising since several studies have reported cross-talks 
Pharmaceuticals 2010, 3                
 
 
53
among JNK, GSK-3β and Cdk5 pathways [42–44]. Plattner et al. described a cross-talk between 
GSK3 and Cdk5, where Cdk5 over-activation leads to GSK3 inhibition [45]. Similarly, the regulation 
of GSK-3β activity by JNK was recently demonstrated by Hu et al. [46]. We could thus speculate that 
inhibition of either Cdk5 or JNK could indirectly influence GSK-3 activity and thus APP 
hyperphosphorylation. 
Unfortunately dissecting further these signaling pathways is difficult: a) due to the rapidity of their 
response and b) because a combinational treatment with these inhibitors was toxic in our model. 
3. Experimental Section 
3.1. Cortical Neuronal Culture  
Primary neuronal cultures were obtained from the cerebral cortex of two days post-natal rats, 
incubated with 200U of papain (Sigma Aldrich) (30’-34 °C), then with trypsin inhibitor (Sigma 
Aldrich) (45’-34 °C) and subsequently mechanically dissociated. All experimental procedures on 
animals were performed in accordance with the European Communities Council Directive of 24 
November 1986 (86/609/EEC) and all efforts were made to minimise animal suffering. Neurons were 
plated in 35 mm dishes (∼7 × 105 cells/dish) pre-coated with 25 μg/mL poly-D-lysine (Sigma Aldrich). 
Plating medium was B27/neurobasal supplemented with 0.5 mM glutamine, 100 U/mL penicillin and 
100 μg/mL streptomycin. The experiments were performed 12 days from plating date, at which time 
neurons are considered differentiated. Neurons were treated with NMDA (100 μM, Sigma Aldrich), 
for 30’-45’-1 h. The inhibitors L803-mts (10 μM, Calbiochem), roscovitine (10 μM, Calbiochem), and 
D-JNKI1 (4 μM, Xigen SA, Lausanne, Switzerland) were administered to neurons 30’ before NMDA 
treatment. L803-mts and Roscovitine were diluted in DMSO. Treatment of neurons with DMSO only 
did not affect the results (data not shown). 
3.2. Cytotoxicity Assay 
Neuronal death was evaluated by a Lactate dehydrogenase assay (LDH), (Cytotox 96 kit, Promega, 
WI). LDH assays were performed in triplicates. 
3.3. Cellular Lysis 
Total protein extracts were obtained by washing cells twice in ice-cold PBS and lysed (20’-4 °C) in 
1% Triton x-100 lysis buffer supplemented with proteases (1 × CPIK, Roche, 10634200) and 
phosphatases (1 μM 4-NPP, Roche, 10030536) inhibitors [47]. 
3.4. Media Proteins Precipitation 
Four hundred μL of medium were incubated with 100 μL of TCA 50% (overnight, 4 °C). After 
centrifugation (14,000 rpm, 30’-4°C), pellets were washed twice with 500 μL acetone and 
reconstituted in 50 μL Urea 4 M. 
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3.5. Western Blot Analysis 
Protein concentrations were quantified using Bradford Assay (Bio-Rad Protein Assay 500-0006) 
and 20 μg of whole cell proteins were separated by 8–10% SDS polyacrylamide gel. PVDF 
membranes were blocked in Tris-buffered saline (5% no fat milk powder, 0.1% Tween20) (1 h, room 
temperature). Primary antibodies were diluted in the same buffer (incubation overnight, 4 °C) using: 
1:2000 anti APP clone 22C11 (APPs) (Chemicon, MAB348), 1:500 anti P-APP (a generous gift from 
Prof. P. Davis, Albert Einstein College of Medicine of Yeshiva University, NY, USA), 1:250 anti 
βAPPs (IBL, 18957), 1:1,000 anti αAPPs clone 6E10 (Signet, 9300), 1:2,000 anti P-GSK3β (Ser9) 
(Cell Signaling Technology, #9336), 1:2000 anti GSK-3β (27C10) (Cell Signaling Technology, 
#9315), 1:1,000 anti P-JNK (Cell Signaling Technology, #4671) 1:1000 anti JNK (Cell Signaling 
Technology, #9252). All blots were normalized to α-tubulin (Santa Cruz Biotechnology, sc-8035) and 
at least three independent experiments were performed. Western blots were quantified by densitometry 
using Quantity One software (Biorad). 
3.6. Cdk5 Kinase Assay 
Cells were washed in ice-cold PBS and lysed (10 h - 4 °C) in RIPA buffer with proteases (1x CPIK, 
Roche, 10634200) and phosphatases (1 μM 4-NPP, Roche, 10030536) inhibitors. Three hundred μg of 
whole cell protein were incubated with 3 μg of anti Cdk5 (C-8) (Santa Cruz Biotechnology, sc-173)  
(2 h - 4 °C) and precipitated with Protein A Sepharose CL-4B (GE-Healthcare, 17-0780-01)  
(1 h - 4 °C). Immunoprecipitated complexes were incubated with 6 μg/μL of Histone H1 and 1 μCi/μL 
of γ-32P-ATP in kinase buffer (10 mM Tris, 1mM DTT, 2 mM EGTA, 10 mM MgCl2, 20 mM ATP) 
(30’, room temperature). Quantification of kinase assays was done using Quantity One software 
(Biorad) and based on at least three independent experiments. 
3.7. Statistical Analysis 
All experiments were repeated using at least three independent culture preparations. Quantitative 
data were statistically analyzed by paired T-test with two-tailed distribution. A p value of < 0.05 was 
considered significant. 
4. Conclusions  
Altogether, these findings suggest that in adult differentiated stressed neurons GSK-3β is the kinase 
responsible for APP phosphorylation in excitotoxic conditions and an appropriate regulation of GSK-
3β activity can be useful for modulation of APP processing. 
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